Literature DB >> 30929179

Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study.

O Abdel-Rahman1,2.   

Abstract

OBJECTIVE: To assess the outcomes of active monitoring (active surveillance or watchful waiting) as an initial management approach compared to upfront definitive local treatments (prostatectomy or radiation therapy) in a cohort of clinically localized prostate cancer patients.
METHODS: Patients with clinically localized prostate cancer registered within the Surveillance, Epidemiology and End Results (SEER) watchful waiting database from 2010-2015 were reviewed. Kaplan-Meier analysis was used to compare overall survival outcomes between patients treated with different initial therapeutic approaches. Multivariate Cox regression analysis (stratified by the risk group) was used to assess potential factors affecting prostate cancer-specific survival.
RESULTS: Using Kaplan-Meier analysis, prostatectomy was associated with better overall survival compared to radiation therapy and active monitoring (P < 0.001). Multivariate Cox regression analysis was then employed to evaluate different factors affecting prostate cancer-specific survival. Among patients with low-risk disease, the following factors were predictive of better prostate cancer-specific survival: younger age (hazard ratio for patients ≥ 70 years versus patients 40-69 years: 2.081; 95% CI 1.277-3.390; P = 0.003), white race (hazard ratio for black race versus white race: 2.575; 95% CI 1.538-4.311; P < 0.001), non-Hispanic ethnicity (hazard ratio versus Hispanic ethnicity: 0.472; 95% CI 0.244-0.910; P = 0.025), and initial treatment with prostatectomy (hazard ratio for prostatectomy versus active monitoring: 0.551; 95% CI 0.371-0.818; P = 0.003).
CONCLUSIONS: Active monitoring seems to be at least as effective as upfront radiation therapy in the management of low-risk disease. Radical prostatectomy is associated with better overall and prostate cancer-specific survival compared to either radiation therapy or active monitoring.

Entities:  

Keywords:  Active surveillance; Outcomes; Prostate cancer; Radiation therapy; Surgery; Watchful waiting

Mesh:

Year:  2019        PMID: 30929179     DOI: 10.1007/s12094-019-02098-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  13 in total

1.  Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.

Authors:  Anna Bill-Axelson; Lars Holmberg; Hans Garmo; Kimmo Taari; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Ove Andrén; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2018-12-13       Impact factor: 91.245

2.  NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

Authors:  Peter R Carroll; J Kellogg Parsons; Gerald Andriole; Robert R Bahnson; Erik P Castle; William J Catalona; Douglas M Dahl; John W Davis; Jonathan I Epstein; Ruth B Etzioni; Thomas Farrington; George P Hemstreet; Mark H Kawachi; Simon Kim; Paul H Lange; Kevin R Loughlin; William Lowrance; Paul Maroni; James Mohler; Todd M Morgan; Kelvin A Moses; Robert B Nadler; Michael Poch; Chuck Scales; Terrence M Shaneyfelt; Marc C Smaldone; Geoffrey Sonn; Preston Sprenkle; Andrew J Vickers; Robert Wake; Dorothy A Shead; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2016-05       Impact factor: 11.908

3.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

Authors:  M Bolla; D Gonzalez; P Warde; J B Dubois; R O Mirimanoff; G Storme; J Bernier; A Kuten; C Sternberg; T Gil; L Collette; M Pierart
Journal:  N Engl J Med       Date:  1997-07-31       Impact factor: 91.245

4.  Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?

Authors:  John J Coen; Adam S Feldman; Matthew R Smith; Anthony L Zietman
Journal:  BJU Int       Date:  2010-09-22       Impact factor: 5.588

5.  Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.

Authors:  Matthew R Cooperberg; Andrew J Vickers; Jeanette M Broering; Peter R Carroll
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

6.  Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Authors:  J L Donovan; F C Hamdy; J A Lane; D E Neal; M Mason; C Metcalfe; E Walsh; J M Blazeby; T J Peters; P Holding; S Bonnington; T Lennon; L Bradshaw; D Cooper; P Herbert; J Howson; A Jones; N Lyons; E Salter; P Thompson; S Tidball; J Blaikie; C Gray; P Bollina; J Catto; A Doble; A Doherty; D Gillatt; R Kockelbergh; H Kynaston; A Paul; P Powell; S Prescott; D J Rosario; E Rowe; M Davis; E L Turner; R M Martin
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

7.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

8.  Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.

Authors:  Kenneth G Nepple; Andrew J Stephenson; Dorina Kallogjeri; Jeff Michalski; Robert L Grubb; Seth A Strope; Jennifer Haslag-Minoff; Jay F Piccirillo; Jay P Ciezki; Eric A Klein; Chandana A Reddy; Changhong Yu; Michael W Kattan; Adam S Kibel
Journal:  Eur Urol       Date:  2013-03-13       Impact factor: 20.096

9.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

10.  Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation.

Authors:  Maxine Sun; Jesse D Sammon; Andreas Becker; Florian Roghmann; Zhe Tian; Simon P Kim; Alexandre Larouche; Firas Abdollah; Jim C Hu; Pierre I Karakiewicz; Quoc-Dien Trinh
Journal:  BJU Int       Date:  2013-08-13       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.